Clinical Trials Logo

DLBCL clinical trials

View clinical trials related to DLBCL.

Filter by:

NCT ID: NCT06150053 Completed - Old Age; Debility Clinical Trials

Dose Dense Chemotherapy in Elderly Patients > 80 Years Old With DLBCL

Start date: July 1, 2018
Phase:
Study type: Observational

Multi-center retrospective analysis of patients with DLBCL aged ≥80 years old treated with R-CHOP-14 compared to other regimens. Patient data including baseline characteristics, histology, dose intensity and treatment outcomes will be extracted from hospital medical electronic records. Relative dose intensity (RDI) will be calculated as the percentage of the dose intensity achieved divided by the intended dose intensity. Primary endpoints are overall (OS), progression-free (PFS) and event-free survival (EFS), defined as time from diagnosis to death, death or progression/relapse, progression/relapse or treatment discontinuation.

NCT ID: NCT05852028 Recruiting - Lymphoma Clinical Trials

A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma

Start date: December 15, 2022
Phase:
Study type: Observational

This study aims to observe and explore the efficacy and safety of selinexor-based regimen in patients with Non-Hodgkin lymphoma

NCT ID: NCT05653271 Recruiting - Follicular Lymphoma Clinical Trials

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Start date: January 21, 2023
Phase: Phase 1
Study type: Interventional

ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies. The ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and efficacy of ACE1831 in patients with CD20-expressing Non-Hodgkin lymphoma.

NCT ID: NCT05552937 Recruiting - DLBCL Clinical Trials

Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Start date: September 6, 2021
Phase: Phase 2
Study type: Interventional

This is a A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT ID: NCT05546268 Recruiting - NSCLC Clinical Trials

Study of Oral MRT-2359 in Selected Cancer Patients

Start date: October 12, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer of any primary site, diffuse large B-cell lymphoma (DLBCL), and tumors with L-MYC or N-MYC amplification. Patients receive escalating doses of a GSPT1 molecular glue degrader MRT-2359 to determine safety, tolerability, maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of MRT-2359. Once the MTD and/or RP2D is identified, additional patients enroll to Phase 2 study, which includes molecular biomarkers stratification or selection, namely expression or amplification of L-MYC and N-MYC genes.

NCT ID: NCT05544019 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Study of SGR-1505 in Mature B-Cell Neoplasms

Start date: April 10, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-1505.

NCT ID: NCT05498636 Not yet recruiting - DLBCL Clinical Trials

SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression

Start date: October 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a phase II multi-center prospective clinical trail which investigates the efficacy and safety of Selinexor combined with prednisone, etoposide and lenalidomide in the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patient with high p53 and/or c-myc expression.

NCT ID: NCT05487170 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Start date: July 12, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumors, including diffuse large B-cell lymphoma (DLBCL). This is a 2-part study (dose escalation, cohort expansion) with sequential enrollment.

NCT ID: NCT05414162 Recruiting - Multiple Myeloma Clinical Trials

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

Start date: May 16, 2022
Phase:
Study type: Observational

Recently chimeric antigen receptor (CAR) T-cell therapy, a new class of chemo therapy, has gained regulatory approval for the treatment of diseases such as B-cell lymphoma. Known side effects include cytokine release syndrome, which has been described to lead to myocarditis, but larger studies exploring this relationship are currently lacking. In this prospective study, the investigators aim to explore the potential effects of CAR T-cell therapy using cardiac MRI on the heart.

NCT ID: NCT05381506 Not yet recruiting - DLBCL Clinical Trials

Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma

O-Gemox
Start date: July 2022
Phase: Phase 2
Study type: Interventional

This study aims to investigate the treatment of refractory or relapsed DLBCL with orelabrutinib and gemox. The primary endpoint is response rate (complete response rate and overall response rate), and the second endpoints are survival time (OS and PFS) and toxicities.